Literature DB >> 18032922

VX-680 inhibits Aurora A and Aurora B kinase activity in human cells.

Rebecca K Tyler1, Natalia Shpiro, Rodolfo Marquez, Patrick A Eyers.   

Abstract

VX-680, also known as MK-0457, is a member of a diverse group of small molecules that inhibit the Aurora kinases, and has shown significant potential as an anti-cancer agent. In keeping with many protein kinase inhibitors, this compound is not a monospecific agent, and its cellular specificity remains largely unknown. In cells, VX-680 blocks mitotic Histone H3 phosphorylation and induces polyploidy and apoptosis, consistent with inhibition of the mitotic protein kinase Aurora B. In this study, we have investigated the effects of VX-680 in proliferating human cancer cells, and demonstrate that it blocks the phosphorylation and activation of both Aurora A and B. Additionally, VX-680 suppresses the phosphorylation of specific substrates of each enzyme, including the Aurora A target TACC3 on Ser558. Exposure to VX-680 induces a monopolar spindle phenotype, delays mitotic progression and rapidly overrides the spindle assembly checkpoint in the presence of spindle poisons. VX-680 also exhibits potent cytotoxicity when compared to the well documented Aurora B inhibitor ZM447439. Taken together, these data identify Aurora A and Aurora B as dual intracellular targets of VX-680.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032922     DOI: 10.4161/cc.6.22.4940

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  40 in total

1.  Activation of Aurora-A kinase by protein partner binding and phosphorylation are independent and synergistic.

Authors:  Charlotte A Dodson; Richard Bayliss
Journal:  J Biol Chem       Date:  2011-11-16       Impact factor: 5.157

2.  Novel E3 ligase component FBXL7 ubiquitinates and degrades Aurora A, causing mitotic arrest.

Authors:  Tiffany A Coon; Jennifer R Glasser; Rama K Mallampalli; Bill B Chen
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

3.  A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.

Authors:  Weiwei Shan; Patricia Y Akinfenwa; Kari B Savannah; Nonna Kolomeyevskaya; Rudolfo Laucirica; Dafydd G Thomas; Kunle Odunsi; Chad J Creighton; Dina C Lev; Matthew L Anderson
Journal:  Clin Cancer Res       Date:  2012-04-25       Impact factor: 12.531

4.  Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells.

Authors:  Jian-Ming Sun; Li-Na Yang; Han Xu; Bin Chang; Hua-Ying Wang; Gong Yang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

5.  Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor.

Authors:  Lih-Ching Hsu; David E Durrant; Ching-Chun Huang; Nai-Wen Chi; Riccardo Baruchello; Riccardo Rondanin; Cinzia Rullo; Paolo Marchetti; Giuseppina Grisolia; Daniele Simoni; Ray M Lee
Journal:  Invest New Drugs       Date:  2011-06-08       Impact factor: 3.850

6.  A framework for identification of actionable cancer genome dependencies in small cell lung cancer.

Authors:  Martin L Sos; Felix Dietlein; Martin Peifer; Jakob Schöttle; Hyatt Balke-Want; Christian Müller; Mirjam Koker; André Richters; Stefanie Heynck; Florian Malchers; Johannes M Heuckmann; Danila Seidel; Patrick A Eyers; Roland T Ullrich; Andrey P Antonchick; Viktor V Vintonyak; Peter M Schneider; Takashi Ninomiya; Herbert Waldmann; Reinhard Büttner; Daniel Rauh; Lukas C Heukamp; Roman K Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-03       Impact factor: 11.205

7.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

Review 8.  Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system.

Authors:  José Alejandro Pérez Fidalgo; Desamparados Roda; Susana Roselló; Edith Rodríguez-Braun; Andrés Cervantes
Journal:  Clin Transl Oncol       Date:  2009-12       Impact factor: 3.405

9.  Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma.

Authors:  Koichi Nishijo; Qing-Rong Chen; Lei Zhang; Amanda T McCleish; Andrea Rodriguez; Min Jung Cho; Suresh I Prajapati; Jonathan A L Gelfond; Gary B Chisholm; Joel E Michalek; Bruce J Aronow; Frederic G Barr; R Lor Randall; Marc Ladanyi; Stephen J Qualman; Brian P Rubin; Robin D LeGallo; Chiayeng Wang; Javed Khan; Charles Keller
Journal:  Cancer Res       Date:  2009-04-01       Impact factor: 12.701

Review 10.  Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors.

Authors:  Kiyoko Umene; Kouji Banno; Iori Kisu; Megumi Yanokura; Yuya Nogami; Kosuke Tsuji; Kenta Masuda; Arisa Ueki; Yusuke Kobayashi; Wataru Yamagami; Hiroyuki Nomura; Eiichiro Tominaga; Nobuyuki Susumu; Daisuke Aoki
Journal:  Biomed Rep       Date:  2013-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.